Cantor Fitzgerald Comments on Strongbridge Biopharma plc’s FY2017 Earnings (SBBP)

Strongbridge Biopharma plc (NASDAQ:SBBP) – Analysts at Cantor Fitzgerald issued their FY2017 earnings per share estimates for Strongbridge Biopharma in a report released on Wednesday. Cantor Fitzgerald analyst E. Piros anticipates that the biotechnology company will post earnings of ($2.84) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Strongbridge Biopharma’s FY2018 earnings at ($1.23) EPS.

A number of other research analysts have also issued reports on SBBP. Zacks Investment Research lowered shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, September 28th. ValuEngine lowered shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Strongbridge Biopharma in a research report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $12.25.

Strongbridge Biopharma (NASDAQ SBBP) opened at $6.10 on Monday. Strongbridge Biopharma has a 52-week low of $2.00 and a 52-week high of $8.85. The company has a current ratio of 4.70, a quick ratio of 4.61 and a debt-to-equity ratio of -1.89.

Several hedge funds and other institutional investors have recently bought and sold shares of SBBP. State of Wisconsin Investment Board acquired a new stake in shares of Strongbridge Biopharma during the 2nd quarter worth approximately $114,000. Rhumbline Advisers acquired a new stake in shares of Strongbridge Biopharma during the 2nd quarter worth approximately $154,000. California State Teachers Retirement System acquired a new stake in shares of Strongbridge Biopharma during the 2nd quarter worth approximately $277,000. Teachers Advisors LLC acquired a new stake in shares of Strongbridge Biopharma during the 2nd quarter worth approximately $297,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Strongbridge Biopharma during the 2nd quarter worth approximately $331,000. Institutional investors and hedge funds own 57.53% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://ledgergazette.com/2017/12/13/cantor-fitzgerald-comments-on-strongbridge-biopharma-plcs-fy2017-earnings-sbbp.html.

About Strongbridge Biopharma

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply